Raised in rural KwaZulu-Natal, South Africa, Carl grew up in a medical household where his father practised as a general practitioner and his mother managed the practice, serving an underserved community. Early exposure to front-line care and low-cost clinical innovation shaped his view that practical ingenuity can materially improve outcomes in resource-limited settings. This experience underpins his commitment to innovation that is both scientifically rigorous and socially equitable, particularly for populations historically underserved by advanced therapies.
Clinically, he works in complex medical and surgical retina, contributing to first-in-human and early-phase gene therapy trials and robotic-assisted microsurgical platforms. His work spans laboratory modelling, clinical trials, and device development, including contributions to retinal organoid platforms, axonal regeneration studies, and robotic retinal vein cannulation protocols.
His work is driven by a central question: how can neural function be restored in diseases once considered irreversibly degenerative, and how can such advances reach underserved populations? He focuses on integrating regenerative biology, gene therapy, and precision surgical systems to develop scalable treatments for neurological disease.
